VistaGen Therapeutics(US:VTGN)2025-11-13 21:34Financial Performance - Net loss for the second quarter of fiscal year 2026 was $19.4 million, compared to a net loss of $13.0 million for the same quarter in fiscal year 2025[7]. - Basic and diluted net loss per common share for the second quarter of fiscal year 2026 was $0.54, compared to $0.42 in the same quarter of the previous year[17]. - The accumulated deficit increased to $442.1 million as of September 30, 2025, from $407.6 million at the end of the previous fiscal year[15]. Revenue and Expenses - Total revenues for the second quarter of fiscal year 2026 were $258,000, compared to $183,000 in the same quarter of the previous year[17]. - Research and development (R&D) expense increased to $15.9 million for the second quarter of fiscal year 2026, up from $10.2 million in the same period last year, reflecting higher expenses related to the PALISADE Program for fasedienol[5]. - General and administrative (G&A) expense was $4.4 million for the second quarter of fiscal year 2026, slightly up from $4.2 million in the prior year[6]. Clinical Trials - The last patient completed the randomized portion of the PALISADE-3 Phase 3 clinical trial, with topline results expected in the fourth quarter of 2025[4]. - The PALISADE-4 Phase 3 trial is set to report topline results in the first half of 2026, following a similar study design as PALISADE-3[4]. Corporate Governance - The company appointed Mr. Paul Edick to its Board of Directors in October 2025[3]. Cash Position - Cash, cash equivalents, and marketable securities totaled $77.2 million as of September 30, 2025[8].